Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate CancerWilliam Morris, Nevin Murray, Scott Tyldesley et al.|International Journal of Radiation Oncology*Biology*Physics|2016Cited by 736
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate CancerNevin Murray, Scott Tyldesley, William Morris et al.|International Journal of Radiation Oncology*Biology*Physics|2017Cited by 319
Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive PatientsMira Keyes, William Morris, Stacy Miller et al.|International Journal of Radiation Oncology*Biology*Physics|2008Cited by 180
Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancerWilliam Morris, Scott Tyldesley, Mira Keyes et al.|Cancer|2012Cited by 112
ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.William Morris, Jeremy Hamm, Scott Tyldesley et al.|Journal of Clinical Oncology|2015Cited by 96